Metropolitan Life Insurance Company (MetLife)’s Insys Therapeutics, Inc. INSY Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-10,223	Closed	-$103K	–	2606
2018 Q3	$103K	Buy	+10,223	New	+$81.5K	﹤0.01%	2437
2017 Q3	–	Sell	-16,871	Closed	-$213K	–	2566
2017 Q2	$213K	Hold	16,871	–	–	﹤0.01%	2299
2017 Q1	$177K	Hold	16,871	–	–	﹤0.01%	2344
2016 Q4	$155K	Hold	16,871	–	–	﹤0.01%	2485
2016 Q3	$199K	Hold	16,871	–	–	﹤0.01%	2339
2016 Q2	$218K	Hold	16,871	–	–	﹤0.01%	2267
2016 Q1	$270K	Hold	16,871	–	–	﹤0.01%	1973
2015 Q4	$483K	Hold	16,871	–	–	﹤0.01%	1644
2015 Q3	$480K	Buy	16,871 +379	+2%	+$13.9K	﹤0.01%	1666
2015 Q2	$592K	Buy	16,492 +2,156	+15%	+$67.2K	﹤0.01%	1631
2015 Q1	$417K	Sell	14,336 -1,754	-11%	-$46.4K	﹤0.01%	1651
2014 Q4	$339K	Buy	16,090 +2,124	+15%	+$42K	﹤0.01%	2044
2014 Q3	$271K	Sell	13,966 -2	-0%	-$31	﹤0.01%	2158
2014 Q2	$218K	Hold	13,968	–	–	﹤0.01%	2458
2014 Q1	$289K	Hold	13,968	–	–	﹤0.01%	2209
2013 Q4	$180K	Buy	+13,968	New	+$194K	﹤0.01%	2542

Other funds holding INSY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s INSY Position: Q4 2018 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Insys Therapeutics, Inc. (INSY) in Q4 2018, closing a stake of 10,223 shares — an estimated $103K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in INSY in Q4 2013 and held it in 16 quarters. The position peaked at $592K in Q2 2015. 113 funds tracked by Wall St. Rank hold INSY as of Q4 2018.

Metropolitan Life Insurance Company (MetLife) reported no remaining Insys Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 10,223 Insys Therapeutics, Inc. shares in Q4 2018, an estimated $103K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Insys Therapeutics, Inc. in Q4 2013 and held it in 16 quarters.
Metropolitan Life Insurance Company (MetLife)'s Insys Therapeutics, Inc. position peaked at $592K in Q2 2015.
113 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2018.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2018, filed 14 Feb 2019.